Compare Agilent Technologies Inc (A) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Agilent Technologies Inc trades at $156.47 (market cap $44.11B), while State Street SPDR S&P Biotech ETF trades at $156.63 (market cap $10.39B). The key difference: Agilent Technologies Inc is far larger — about 4.2× State Street SPDR S&P Biotech ETF's market cap, and Agilent Technologies Inc pays a 0.65% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Agilent Technologies Inc for 37 Days and State Street SPDR S&P Biotech ETF for 34 Days on average.
| A | XBI | |
|---|---|---|
Market Cap | $44.11B | $10.39B |
Volume | 4,849,519 | 9,833,815 |
Sector | Health | Broad Market / Factor |
52-Week High | $158.93 | $169.55 |
52-Week Low | $110.24 | $95.60 |
Typical Hold Time | 37 Days | 34 Days |
Enterprise Value | $46.30B | — |
Dividend Yield | 0.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $156.47, up 1.81% on the day, with a bullish technical outlook and strong institutional interest. Recent Q3 2026 earnings beat expectations with EPS of $1.62 versus $1.49 expected, and the company raised full-year guidance. Valuation ratios are elevated with a P/E of 30.84 and P/S of 6.01, reflecting premium pricing for its consistent profitability and market position in life sciences tools.
The stock offers upside to the consensus price target of $170, supported by solid fundamentals and positive analyst sentiment, but faces risks from high valuation multiples and potential market volatility. Revenue growth and margin expansion in recent quarters provide a foundation for continued performance, though investors should weigh these against macroeconomic pressures on research spending.
XBI trades at $156.63, up 1.59% today, with a bullish technical signal from moving averages and support at $153. The ETF's equal-weight structure across 150+ biotech firms benefits from M&A activity and positive clinical catalysts, though key valuation ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and capital flow improvements.
Outlook remains positive given strong momentum and sector tailwinds, but high volatility and policy risks warrant caution. Analyst consensus is neutral with 100% hold rating, reflecting balanced risk-reward amid elevated prices near 2021 highs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
